Shire wins a blockbuster OK for pipeline star lanadelumab, boosting Takeda’s $62B takeover deal
The FDA wasted no time in stamping their quick approval on Shire’s marketing application for lanadelumab — one of the year’s top likely blockbusters in the industry pipeline. And that’s a critical endorsement for Takeda, which wants to provide some compelling reasons behind its $62 billion deal to buy Shire to help satisfy its critics.
The drug will now hit the market as Takhzyro. A spokesperson for the company says that is pronounced “Tek-zye-roe.” And you can find out what it will be priced at in the next week.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
